NCT04528212View on ClinicalTrials.gov

Fenofibrate Versus Curcumin in Type 2 Diabetic Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 1, 2020

Primary Completion Date

November 30, 2021

Study Completion Date

December 1, 2021

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Glimepiride Tablets

Glimepiride (4 mg) per Day

DRUG

glimepiride plus fenofibrate

Glimepiride (4 mg) plus Fenofibrate (160 mg) per Day

DRUG

glimepiride plus curcumin

Glimepiride (4 mg) plus Curcumin (1100 mg) With 5mg Black Pepper per Day

Trial Locations (1)

31527

Tanta University Hospital, Tanta

All Listed Sponsors
lead

Rehab Werida

OTHER

NCT04528212 - Fenofibrate Versus Curcumin in Type 2 Diabetic Patients | Biotech Hunter | Biotech Hunter